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Rheumatoid arthritis
AbstrAct
Background tapering of anti-tumour necrosis factor (tnF) 
therapy appears feasible, safe and effective in selected 
patients with rheumatoid arthritis (ra). Depression is highly 
prevalent in ra and may impact on flare incidence through 
various mechanisms. this study aims to investigate if 
psychological states predict flare in patients’ dose tapering 
their anti-tnF therapy.
Methods this study is a post-hoc analysis of the Optimizing 
tnF tapering in ra trial, a multicentre, randomised, open-
label study investigating anti-tnF tapering in ra patients with 
sustained low disease activity. Patient-reported outcomes 
(Health assessment Questionnaire, euroQol 5-dimension 
scale, Functional assessment of chronic illness therapy 
fatigue scale (Facit-F), 36-item Short Form Survey (SF-36)) 
were collected at baseline. the primary outcome was flare, 
defined as an increase in 28-joint count Disease activity 
Score (DaS28) ≥0.6 and ≥1 swollen joint. Discrete-time 
survival models were used to identify patient-reported 
outcomes that predict flare.
Results ninety-seven patients were randomised to taper 
their anti-tnF dose by either 33% or 66%. Forty-one patients 
flared. Higher baseline DaS28 score was associated with 
flare (adjusted Hr 1.96 (95% ci 1.18 to 3.24), p=0.01). 
Disability (SF-36 physical component score), fatigue 
(Facit-F) and mental health (SF-36 mental health subscale 
(MH)) predicted flare in unadjusted models. in multivariate 
analyses, only SF-36 MH remained a statistically significant 
predictor of flare (adjusted Hr per 10 units 0.74 (95% ci 0.60 
to 0.93), p=0.01).
Conclusions Baseline DaS28 and mental health status 
are independently associated with flare in patients who 
taper their anti-tnF therapy. Fatigue and function also 
associate with flare but the effect disappears when 
adjusting for confounders. given these findings, mental 
health and functional status should be considered in anti-
tnF tapering decisions in order to optimise the likelihood 
of success.
Trial registration numbers eudract number: 2010-
020738-24; iSrctn: 28955701; Post-results.
BaCkgRound
Disease activity-guided dose tapering or 
discontinuation of anti-tumour necrosis 
factor (TNF) therapy appears to be feasible, 
safe and effective in a selected proportion 
of patients with rheumatoid arthritis (RA).1 
However beyond the demonstration of clin-
ical remission by 28-joint count Disease 
Activity Score (DAS28), there are no stand-
ardised methods to identify patients in whom 
treatment tapering is likely to be successful.2 
Approximately one to two thirds of patients 
flare when tapering or stopping anti-TNF 
treatment.3 There is growing evidence that 
Key messages
What is already known about this subject?
 ► anti-tumour necrosis factor (tnF) dose tapering is 
increasingly used in rheumatoid arthritis, offering 
significant cost savings.
What does this study add?
 ► One-third of patients who taper their anti-tnF dose 
will flare over a 12-month period.
 ► Higher 28-joint count Disease activity Score score 
at baseline, along with disability, fatigue and mental 
health scores, is predictive of flare.
How might this impact on clinical practice?
 ► this information will help physicians make more 
personalised treatment decisions.
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even short-term flare episodes contribute to worsening 
joint damage4 and poorer functional outcome.5 The 
ability to accurately predict who may flare is likely to 
constitute a major improvement over the current trial-
and-error tapering. At present, there are no consistently 
identified predictive markers for successful dose reduc-
tion.6 
Mental health constitutes a plausible marker for 
disease flare since poor mental health may influence 
symptom reporting and interfere with self-management 
behaviours. Mental health disorder is common in RA 
with major depression present in 17% of patients and 
clinically significant depressive symptoms are found in up 
to 50%.7 Worse mental health is associated with increased 
pain and fatigue8 and higher disease activity due to its 
influence on the tender joint count and the patient 
global assessment components of the DAS28 score.9
Worse mental health is negatively associated with 
remission in patients on anti-TNF therapy.10 11 For those 
with stable disease, mental health has been identified as 
an independent factor for flare.12 In addition to mental 
health, concurrent fibromyalgia13 and poorer physical 
quality-of-life measures14 have been shown to be asso-
ciated with an increased risk of flare in patients with 
low disease activity (LDA) on stable anti-TNF therapy, 
although it is less clear whether these measures are a 
reflection of worse mental health and inflammation.
To date, there are no studies directly addressing the 
role of mental health (depression, anxiety or low mood), 
fatigue and functional states in predicting flares in 
patients tapering their biological therapy. The aim of our 
study was to assess if baseline mental health and func-
tional states measured by self-report screening question-
naires predict flare in RA patients with LDA who undergo 
treatment tapering of their anti-TNF agent as part of the 
Optimizing TNF Tapering in RA (OPTTIRA) trial.
MeTHods
study design and patients
This study is a post-hoc analysis of the OPTTIRA trial. 
OPTTIRA was a multicentre, prospective, randomised, 
open-label study investigating anti-TNF tapering in estab-
lished patients with RA who are in sustained LDA.15 The 
OPTTIRA trial consists of two phases: the randomised, 
controlled, open-label, proof-of-principle phase (0–6 
months), followed by the open exploratory phase (6–12 
months) for patients who completed the initial trial 
period. All patients were receiving anti-TNF agents. They 
had met existing National Institute for Health and Care 
Figure 1 Consort flow chart for Optimizing TNF Tapering in RA trial. IL, interleukin; TNF, tumour necrosis factor.
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Excellence criteria for starting these agents and had 
achieved a sustained good response, defined as DAS28 
scores of ≤3.2 without an increase of >0.6, during the 
previous  3-month period. Patients were taking either 
etanercept or adalimumab at standard doses (50 mg/
week and 40 mg/fortnight, respectively) and at least one 
concomitant conventional synthetic disease-modifying 
antirheumatic drug (DMARD).
In the proof-of-principle phase of the study (0–6 
months), 50 patients were randomised to a control group 
(constant anti-TNF dose) and 47 patients to one of two 
experimental groups—group 1 (26 patients) tapered 
anti-TNF by 33% while group 2 (21 patients) tapered 
anti-TNF by 66%. At 6 months, patients who had not 
flared during the initial phase of the study entered a 
second phase (6—12 months). Those in experimental 
groups 1 and 2 continued tapering anti-TNF therapy 
to complete cessation, while patients from the control 
group were randomised into control group A (21 patients) 
who tapered anti-TNF by 33% or control group B (17 
patients) who tapered by 66% (figure 1). This post-hoc 
analysis includes the entire cohort.
 Written informed consent was obtained from all 
patients.
Clinical assessments
Baseline variables including patient demographics, 
RA disease duration and concomitant conventional 
synthetic DMARDs were collected prior to anti-TNF 
tapering. Disease-related and patient-reported outcome 
measures that were assessed included the Health Assess-
ment Questionnaire (HAQ), Functional Assessment 
of Chronic Illness Therapy fatigue scale (FACIT-F), 
EuroQol 5-dimension scale (EQ-5D-3L) and the 36-Item 
Short Form Survey (SF-36). Mental health was opera-
tionalised using the depression and anxiety question 
within the EQ-5D and the Mental Health (MH) subscale 
within the SF-36. The MH subscale shares similarities 
with generic depression screening questionnaires, such 
as the Nine-item Patient Health Questionnaire and 
has been demonstrated to perform reasonably well as 
a screening tool for depression in RA.16 17 A MH score 
cut-off of ≤56 was validated to detect depression in RA, 
with a sensitivity and specificity of 92.6% and 73.2%, 
respectively.17
The primary outcome was flare, defined as an increase 
in DAS28 scores≥0.6 resulting in a DAS28 >3.2. The 
increase in DAS28 scores must include an increase in 
swollen joint count and be present on two occasions 
at least 1 week apart. An increase in DAS28 score ≥1.2 
resulting in DAS28 >3.2 between scheduled visits was also 
defined as flare irrespective of changes in the swollen 
joint count.
statistical analysis
Descriptive statistics were provided with mean (±SD, 
median (IQR)) or frequencies depending on data distri-
bution.
Discrete-time survival regression models (comple-
mentary log–log link) were used to identify predictors 
of time to flare.18 Flare in the previous 3-month interval 
was the outcome variable and clinical and functional 
measurements the predictor variables. A multivariate 
discrete-time survival model was applied adjusting for 
potential confounders: baseline age, gender, treatment 
arm, DAS28 and body mass index (BMI). A p value <0.05 
was regarded as being statistically significant. As this was 
an exploratory study, no correction for multiple hypoth-
esis testing was performed. A sensitivity analysis was also 
performed looking at the predictor variables at the assess-
ment point immediately prior to the flare event.
Missing data were addressed using a multiple imputa-
tion module (online online supplementary annex 1). For 
subjects with missing outcomes, the baseline outcomes 
and other explanatory covariates (treatment group, sex, 
age, ethnicity and disease duration) were used to impute 
the missing data, assuming unobserved measurements 
were missing at random. All analyses were performed 
with STATA V.14.1 statistical software.
ResulTs
Patient characteristics
Between April 2011 and June 2013, 244 patients were 
screened, 103 were randomised and 97 accepted their 
allocated treatment (figure 1). Baseline characteris-
tics are given in table 1. The majority of patients were 
on methotrexate in combination with their anti-TNF 
therapy (n=67, 69%) and the median disease duration 
was 11 years (IQR 7–17). Seventy-three (75%) fulfilled 
DAS28 remission criteria (DAS28 <2.6).
HAQ scores >1, suggesting moderate to severe 
disability, were observed in 34% of patients. Median 
HAQ score was 0.5 (IQR 0.13–1.38). The median EQ-5D 
score was 0.76 (0.66–1.00) on a scale, where higher scores 
represent better quality of life. Twenty-two per cent of 
the cohort admitted to feeling symptoms of depression 
and anxiety on the EQ-5D depression question. Patients 
scored higher on the mental component of the SF-36 
than the physical component (57 (49–60) vs 45 (34–52)), 
on a scale of 0–100 where higher scores represent better 
health states. The median SF-36 MH subscale score was 
84. A score of ≤56, the MH cut-off used to detect depres-
sion was observed in 11% of patients.
Characteristics of flare
Forty-one patients (42%) flared over the 12-month 
period. In the first phase of the study (0–6 months), three 
patients who tapered anti-TNF by 33% (experimental 
group 1) and six patients who tapered anti-TNF by 66% 
(experimental group 2) flared, while eight patients in the 
control arm flared (figure 1).
In the second phase of the study (6–12 months), nine 
patients in experimental group 1 and four patients in 
experimental group 2 who were continuing tapering of 
anti-TNF therapy to complete cessation flared. In the 
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control group, three patients who tapered anti-TNF by 
33% (control group A) and eight patients who tapered 
anti-TNF by 66% (control group B) flared.
There was a statistically significant difference in base-
line SF-36 MH and FACIT-F scores between patients who 
flared compared with those who did not; MH score (flare: 
80 (68–88) vs no flare: 88 (72–92), p=0.04) and FACIT-F 
score (flare: 39 (31–44) vs no flare: 43 (37–46), p=0.03). 
The lower the score the more severe the symptoms of 
depression or fatigue, respectively. There was a greater 
proportion of patients categorised with depression in the 
flare group by MH score ≤56 (8% vs 3%, p=0.03), but 
there was no difference when depression was categorised 
by the EQ-5D anxiety and depression question (11% vs 
10%, p=0.29). There were no differences in baseline 
EQ-5D or HAQ score between the two groups.
Prediction of flare
Our primary analyses considered baseline patient char-
acteristics in a flare prediction model (table 2). A higher 
DAS28 score at study entry was associated with increased 
hazard for flare. This association remained significant 
even after adjusting for co-variates (HR 1.96 (95% CI 
1.18 to 3.24), p=0.04).
Disability (SF-36 physical component) predicted flare 
in the unadjusted model (HR per 10 units 0.74 (95% 
CI 0.55 to 0.99), p=0.05). Fatigue (FACIT-F) and mental 
health (SF-36 MH) also predicted flare in univariate 
models (FACIT-F HR per 10 units 0.68 (95% CI 0.47 to 
0.99), p=0.04) (MH HR per 10 units 0.81 (95% CI 0.68 to 
0.96), p=0.01). In adjusted analyses, only MH remained a 
statistically significant predictor of flare (HR per 10 units 
0.74 (95% CI 0.60 to 0.93), p=0.01). HAQ was not a statis-
tically significant predictor of flare, although the direc-
tion of association was consistent.
We also analysed the predictor variables at the assess-
ment point immediately prior to the flare event. We use 
this time-dependant analysis to determine whether flare 
is predicted by variables measures at closer time points to 
the event. There was no clinically meaningful difference 
in the point estimates of effects (online supplementary 
data). The imputation model confirmed these findings.
disCussion
To our knowledge, this is the first study to date to inves-
tigate the effect of mental health and functional states 
Table 1 Baseline demographics and clinical characteristics
Demographic variables
Patients 97
Age, years* 57 (11)
Female gender 72 (74%)
Disease duration,
years†
11.3 (7.3–16.7)
Smoking status 
  Ex-smoker 32 (38%) 
  Current 12 (14%) 
BMI 25.4 (22.6–29.4)
Clinical variables
Treatment csDMARD 
  Methotrexate 67 (69%) 
  Hydroxychloroquine 7 (7%) 
  Sulfasalazine 4 (4%) 
  Leflunomide 4 (4%) 
  csDMARD combination 15 (15%) 
Treatment bDMARD 
  Adalimumab 54 (56%) 
  Etanercept 43 (44%) 
Radiographic damage
(Larsen score)†
51 (16–82)
Tender joint counts
(28 joints)†
0 (0–1)
Swollen joint counts
(28 joints)†
0 (0–0)
Patient global assessment 
(mm)†
5 (1–16)
Erythrocyte sedimentation 
rate(mm/hour)†
8 (5–19)
C-reactive protein (mg/L)† 5 (2–6)
DAS28-ESR† 2.0 ()
DAS28-ESR<2.6 (remission) 73 (75%)
Mental health variables
Health Assessment 
Questionnaire score†
0.50 (0.13–1.38)
EQ-5D-3L score† 0.76 (0.66–1.00)
EQ-5D-3L depression question 21 (22%)
FACIT fatigue scale 41 (35–46)
SF-36 
  Physical component 
summary* 
45 (34 – 52) 
  Mental component summary* 57 (49 – 60) 
  SF-36 MH score† 84 (72–92)
  SF-36 MH (score<56) 10 (10%)
Treatment arm
Experimental 1 (taper 1/3rd) 26 (27%) 
Experimental 2 (taper 2/3rd) 21 (22%) 
Continued
Control A (taper 1/3rd) 27 (28%) 
Control B (taper 2/3rd) 23 (24%) 
All values are gives as number (%) unless otherwise specified.
*Mean (SD).
†Median (p25–p75).
BMI, body mass index;  bDMARD, biological DMARD; csDMARD, 
conventional synthetic DMARD; EQ-5D, EuroQol 5-dimension 
scale; FACIT-F, Functional Assessment of Chronic Illness Therapy 
fatigue scale; SF-36 MH, SF-36 Mental Health subscale.
Table 1 Continued 
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on the risk of flare when tapering anti-TNF therapy in 
patients with RA. Disability, fatigue and mental health as 
measured by patient-reported outcomes including SF-36 
physical component, FACIT-F and the SF-36 mental 
health subscale predicted flare. Mental health as defined 
by the SF-36 MH was the only independent predictor 
of flare after adjusting for age, gender, treatment arm, 
DAS28 and BMI. The MH score ranges from 0 to 100, 
with lower scores indicating more severe depressive symp-
toms. With every 10-point decrease in MH score, the risk 
of flare increases by 19%. Both HAQ and EQ-5D were 
not statistically significant predictors of flare, although 
the direction of association was consistent.
Unlike the other variables, the SF-36 MH subscale 
specifically assesses depressive symptoms with items 
relating to low mood, nerves and restlessness. It shares 
similarities with generic depression screening tools, 
such as the PHQ9.17 In comparison, the other baseline 
measures assess quality of life and general mental health. 
For example, the SF-36 mental component summary 
is calculated by positively weighting the MH and three 
other psychological subscales (vitality, social function, 
emotional role). This suggests that depression alone can 
independently predict flare in patients who taper their 
anti-TNF agents. Depression can impact patients’ percep-
tion and interpretation of their symptoms19 and is asso-
ciated with poor health behaviour including reduced 
treatment adherence.20 There is limited literature on the 
impact of depression in RA tapering cohorts. In patients 
who remain on stable treatment, depression has been 
shown to predict future disease activity, flare12 21 and 
a poorer response to treatment.22 23 In drug tapering 
studies, HAQ is the only patient-reported measure that 
has been evaluated, with lower scores associated with 
successful tapering in univariate analyses.24–26
The nocebo effect is a well-known phenomenon where 
patients’ concerns and expectations about the value of 
a therapeutic intervention negatively influence adher-
ence and treatment response. This has been considered 
in patients switching biologics from bio-originators to 
biosimilars, to explain a deterioration in therapeutic 
Table 2 Unadjusted and adjusted HRs for flare
Unadjusted HRs
HR (95% CI) P values
Demographic variables
Age, years 1.02 (0.99 to 1.04) 0.24
Gender (male) 0.87 (0.42 to 1.82) 0.72
Disease duration, years 1.01 (0.97 to 1.04) 0.78
BMI 1.03 (0.97 to 1.09) 0.38
Treatment arm
  Taper 1/3rd 1.28 (0.55 to 2.98) 0.57 
  Taper 2/3rd 2.51 (1.06 to 5.96) 0.04 
Clinical variables
DAS28 
  Unadjusted 1.86 (1.19 to 2.92) 0.01 
  Adjusted (age, gender, trial 
arm) 
1.96 (1.18 to 3.24) 0.01 
Mental health variables
HAQ-DI 
  Unadjusted 1.45 (0.99 to 2.13) 0.06 
  Adjusted (age, gender, trial 
arm) 
1.43 (0.91 to 2.29) 0.13 
  Adjusted (age, gender, trial 
arm, BMI, DAS28) 
1.16 (0.72 to 1.87) 0.53 
EQ-5D 
  Unadjusted 0.28 (0.07 to 1.24) 0.09 
  Adjusted (age, gender, trial 
arm) 
0.29 (0.06 to 1.38) 0.12 
  Adjusted (age, gender, trial 
arm, BMI, DAS28) 
0.51 (0.10 to 2.58) 0.42 
EQ-5D depression anxiety 
  Unadjusted 1.42 (0.70 to 2.87) 0.33 
  Adjusted (age, gender, trial 
arm) 
1.37 (0.64 to 2.96) 0.41 
  Adjusted (age, gender, trial 
arm, BMI, DAS28) 
1.51 (0.70 to 3.28) 0.29 
FACIT-F (per 10 unit) 
  Unadjusted 0.68 (0.47 to 0.99) 0.04 
  Adjusted (age, gender, trial 
arm) 
0.78 (0.48 to 1.14) 0.18 
  Adjusted (age, gender, trial 
arm, BMI, DAS28) 
0.77 (0.50 to 1.16) 0.20 
SF-36 PCS (per 10 unit) 
  Unadjusted 0.74 (0.55 to 0.99) 0.05 
  Adjusted (age, gender, trial 
arm) 
0.72 (0.52 to 1.00) 0.05 
  Adjusted (age, gender, trial 
arm, BMI, DAS28) 
0.86 (0.60 to 1.23) 0.41 
SF-36 MCS (per 10 unit) 
  Unadjusted 0.90 (0.62 to 1.31) 0.58 
  Adjusted (age, gender, trial 
arm) 
0.93 (0.60 to 1.44) 0.74 
  Adjusted (age, gender, trial 
arm, BMI, DAS28) 
0.83 (0.54 to 1.28) 0.41 
Continued
Unadjusted HRs
HR (95% CI) P values
SF-36 MH (per 10 unit) 
  Unadjusted 0.81 (0.67 to 0.96) 0.01 
  Adjusted (age, gender, trial 
arm) 
0.80 (0.65 to 0.98) 0.03 
  Adjusted (age, gender, trial 
arm, BMI, DAS28) 
0.75 (0.60 to 0.93) 0.01 
BMI, body mass index; DAS28, 28-joint count Disease Activity 
Score; EQ-5D, EuroQol 5-dimension scale; FACIT, Functional 
Assessment of Chronic Illness Therapy fatigue scale; HAQ-
DI, Health Assessment Questionnaire Disability Index; SF36 
MCS, mental component summary; SF36 MH, Mental Health 
subscale; SF36 PCS, physical component summary. 
Table 2 Continued 
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benefit,27 although the clinical features are complex and 
undefined.28 It is acknowledged that patients with mental 
illness are more susceptible to the nocebo effect27 and 
it is plausible that this may also contribute to the asso-
ciation between unsuccessful drug tapering and flare in 
patients with poor mental health.
In this study, univariate analyses demonstrated that 
measures of quality-of-life status helped predict flare. 
However in the adjusted model, these measures did not 
remain statistically significant predictors. It is possible 
that measures of psychological and functional well-being 
correlate with other factors in a causal pathway; for 
example, fatigue affects components of the DAS28 score, 
increasing the overall score and amplifying the risk of 
flare. Thus when adjusted for DAS28, the predictive value 
of these measures is lost. The direction of effect does not 
change in the adjusted model and it is likely that the loss 
in statistical significance is related to a loss of power due 
to the limited OPTTIRA sample size.
A higher DAS28 score at entry was also predictive of 
flare in this study. The current literature on the predic-
tive value of DAS28 at point of anti-TNF tapering is 
conflicting. DAS28 was found to be a predictor of 
successful drug tapering in only half of the studies in 
which it was evaluated.6 In two anti-TNF discontinuation 
studies (remission induction by Remicade in RA29 and 
the HONOR study30), analyses indicated a lower DAS28 
cut-off value of 2.22 and 1.98, respectively, was required 
for successful drug tapering. The OPTIRA patient cohort 
was an LDA cohort, in which a quarter of patients’ base-
line DAS28 scores were greater than the remission cut-off 
of 2.6. This may explain why DAS28 was shown to be a 
strong predictor of flare compared with exclusive remis-
sion cohorts.
When considering these findings, it is important to note 
the limited success in identifying biomarkers that predict 
dose tapering. Serological status (anti-cyclic citrullinated 
peptide antibodies),31 ultrasound Doppler-detected 
synovitis31 32 and the multi-biomarker disease activity 
score33 have been individually evaluated. Although posi-
tive findings should be interpreted with caution due to 
reporting bias and multiple testing. A systematic review 
of all tapering studies identified adalimumab through 
level, the Sharp/van der Heijde erosion score and dura-
tion of symptoms at start of biologic to predict successful 
tapering.6
The proportion of patients with depression in this 
population, defined by MH score ≤56, was relatively 
low. Clinical remission may be a significant influence of 
improvement in mental health states for patients both 
with and without baseline depression. It is recognised 
that patients who achieve clinical remission experience 
improvements in their depression and anxiety symp-
toms.21 This may be due to reduction in pain and fatigue 
levels from control of RA disease activity or it may be 
directly attributable to a reduction in pro-inflamma-
tory cytokines including TNF-α, which can modulate 
neurotransmitter systems.34 It is possible that consent bias 
resulted in the inclusion of ‘happier’ patients, who are 
less likely to suffer from mental health disorder. Of the 
244 patients screened, only 103 consented and entered 
randomisation (consort flow chart). It has been reported 
that consenters are less likely to have a sensitive diagnosis 
such as a mood disorder,35 36 and those who do are less 
likely to continue participation in clinical studies and can 
contribute to missing data.
Lastly, the OPTTIRA trial used a stringent definition 
of flare, which included the requirement for at least 
one swollen joint count to account for the increase 
in DAS28. In prior studies identifying an association 
between psychological measures and disease activity, 
the increase in DAS28 score has been driven primarily 
by tender joint count or global assessment score22 which 
may be influenced by psychosocial factors.37 In contrast, 
the captured flare events in the OPTTIRA study are more 
likely to represent a genuine inflammatory disease flare 
and less likely influenced by low mood or depression. 
The OMERACT RA flare group recognises the limita-
tion of DAS28 in defining flare events. There is disparity 
between the classification of a flare by a patient, their 
physician and the DAS28 criteria. Agreement across these 
classifications is higher in patients in remission or LDA.38 
A consensus-based core domain has been developed to 
provide a greater patient-centred tool to identify and 
measure flare in RA.38 39 Improving the definition of flare 
may help identify and precisely quantify inflammatory 
flares which is vital in guiding successful drug tapering.
This study has several strengths. OPTTIRA was a prag-
matically designed study, with less stringent inclusion 
and exclusion criteria and thus the cohort is far more 
representative than a highly selective clinical trial popu-
lation. The inclusion of patients with LDA in addition to 
those in remission increases the generalisability of our 
findings. Lastly, this was a deeply phenotyped cohort with 
extensive clinical and laboratory data at multiple time 
points across the study period including precise date of 
flare events.
There are potential limitations to this study. First, we 
must acknowledge the limitation of the OPTTIRA study 
sample size. The failure to detect other predictors of 
flare could reflect a type II error and the study’s lack 
of power preclude robust conclusions. The high scores 
from the MH compared with population point-prev-
alence estimates may reflect that our sample size was 
not large enough to capture sufficient patients with 
depression. Second, the study duration was relatively 
short and may not have provided a long enough period 
to allow patients to flare. We did not record or analyse 
sustained flares which may prove more important than 
potential transient flares. Lastly, there are a multitude 
of methods available to detect health-related quality of 
life and depression. The gold standard method for diag-
nosis of depression is psychiatric interview and diagnosis 
according to Diagnostic and Statistical Manual or Inter-
national Classification of Diseases criteria. Despite using 
both a disease-specific assessment (HAQ) and generic 
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measures applicable to both the normal population 
and other disease groups (SF-36 and EQ-5D), these are 
ultimately only screening tools. Estimates according to 
screening tools are based on predefined thresholds and 
tend to prioritise sensitivity over specificity which may 
result in overestimations of prevalence of depression.7
ConClusion
Baseline depression, measured by SF-36 mental 
health scale and DAS28, independently predict flare 
events in patients with sustained LDA who taper their 
anti-TNF agents. In addition to baseline depression, a 
range of psychological and functional states measured by 
patient-reported outcomes also predicted flare events in 
the OPTIRRA cohort although these were not be demon-
strated to be independent risk factors. Based on these 
findings, an assessment of mental health and functional 
status should be considered prior to dose reduction.
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